CN111247152B - 作为激酶抑制剂的环状亚氨基嘧啶衍生物 - Google Patents

作为激酶抑制剂的环状亚氨基嘧啶衍生物 Download PDF

Info

Publication number
CN111247152B
CN111247152B CN201880067947.0A CN201880067947A CN111247152B CN 111247152 B CN111247152 B CN 111247152B CN 201880067947 A CN201880067947 A CN 201880067947A CN 111247152 B CN111247152 B CN 111247152B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
mmol
isotopic derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880067947.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111247152A (zh
Inventor
陈晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bichen Pharmaceutical Technology Co ltd
Original Assignee
Bichen Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bichen Pharmaceutical Technology Co ltd filed Critical Bichen Pharmaceutical Technology Co ltd
Publication of CN111247152A publication Critical patent/CN111247152A/zh
Application granted granted Critical
Publication of CN111247152B publication Critical patent/CN111247152B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880067947.0A 2017-09-20 2018-09-20 作为激酶抑制剂的环状亚氨基嘧啶衍生物 Active CN111247152B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561142P 2017-09-20 2017-09-20
US62/561,142 2017-09-20
PCT/US2018/052047 WO2019060611A1 (en) 2017-09-20 2018-09-20 CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES

Publications (2)

Publication Number Publication Date
CN111247152A CN111247152A (zh) 2020-06-05
CN111247152B true CN111247152B (zh) 2024-07-16

Family

ID=64457074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880067947.0A Active CN111247152B (zh) 2017-09-20 2018-09-20 作为激酶抑制剂的环状亚氨基嘧啶衍生物

Country Status (10)

Country Link
US (2) US11254680B2 (enExample)
EP (1) EP3684772B1 (enExample)
JP (1) JP7394768B2 (enExample)
KR (1) KR102796209B1 (enExample)
CN (1) CN111247152B (enExample)
AU (1) AU2018338098B2 (enExample)
BR (1) BR112020005455A2 (enExample)
CA (1) CA3076202A1 (enExample)
MX (1) MX2020003126A (enExample)
WO (1) WO2019060611A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005455A2 (pt) * 2017-09-20 2020-09-24 Abm Therapeutics Corporation derivados de iminopirimidina cíclica como inibidores de cinase
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PL4073044T3 (pl) * 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe inhibitory BRAF jako związki przełamujące paradoks
PE20231651A1 (es) 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
CN116710453A (zh) * 2020-08-07 2023-09-05 璧辰医药技术股份有限公司 激酶抑制剂及其用途
CN114380697A (zh) * 2021-11-30 2022-04-22 上海毕得医药科技股份有限公司 一种n-甲基乙基胺盐酸盐的制备工艺
TW202409040A (zh) * 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN117209503B (zh) * 2023-09-13 2025-10-17 苏州翔实医药发展有限公司 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104703599A (zh) * 2012-09-14 2015-06-10 永恒生物科技公司 作为蛋白激酶抑制剂的氨基异喹啉衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1549652T1 (sl) * 2002-09-30 2009-04-30 Bayer Healthcare Ag Kondenzirani azolpirimidinski derivati
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
US8093239B2 (en) 2007-06-01 2012-01-10 Glaxosmithkline Llc Imidazopyridine kinase inhibitors
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
US9216981B2 (en) * 2010-12-02 2015-12-22 Medpacto, Inc. Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient
US20130023531A1 (en) * 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
US9688635B2 (en) * 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9321762B2 (en) * 2013-12-11 2016-04-26 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
CN105272970A (zh) * 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途
KR102433758B1 (ko) * 2014-07-16 2022-08-19 재단법인 생물기술개발중심 퀴녹살린 화합물, 그것의 제조 방법 및 용도
BR112020005455A2 (pt) * 2017-09-20 2020-09-24 Abm Therapeutics Corporation derivados de iminopirimidina cíclica como inibidores de cinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN104703599A (zh) * 2012-09-14 2015-06-10 永恒生物科技公司 作为蛋白激酶抑制剂的氨基异喹啉衍生物

Also Published As

Publication number Publication date
EP3684772A1 (en) 2020-07-29
US20220251089A1 (en) 2022-08-11
US20200247813A1 (en) 2020-08-06
KR102796209B1 (ko) 2025-04-16
JP7394768B2 (ja) 2023-12-08
RU2020113707A (ru) 2021-10-20
AU2018338098A1 (en) 2020-05-07
US11932647B2 (en) 2024-03-19
CN111247152A (zh) 2020-06-05
EP3684772C0 (en) 2023-12-06
CA3076202A1 (en) 2019-03-28
JP2020534373A (ja) 2020-11-26
EP3684772B1 (en) 2023-12-06
AU2018338098B2 (en) 2024-02-22
MX2020003126A (es) 2020-10-01
BR112020005455A2 (pt) 2020-09-24
US11254680B2 (en) 2022-02-22
KR20200055034A (ko) 2020-05-20
RU2020113707A3 (enExample) 2021-12-23
WO2019060611A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
CN111247152B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
CN109963854B (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2021203768A1 (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
US9890168B2 (en) 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
KR102887500B1 (ko) Egfr 억제제 및 이의 제조방법 및 응용
CN107428742A (zh) 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
WO2019154294A1 (zh) 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用
CN110156783B (zh) 作为pi3k/mtor抑制剂的嘧啶基取代的稠合喹啉化合物
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
WO2022002100A1 (zh) 新型苯并咪唑化合物
WO2019174607A1 (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
JP2023554391A (ja) キナーゼ阻害剤およびそれらの使用
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
HK40031627B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
CN110684020B (zh) 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2025026195A1 (zh) 取代的含氮双环化合物及其用途
CN115403568A (zh) 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
WO2025087295A1 (zh) 一种pi3k抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40031627

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant